Brolucizumab

證據等級: L5

預測適應症: 4 個

---

目錄

1. Brolucizumab
2. BROLUCIZUMAB: Evaluation Incomplete — Critical Data Gaps Identified
   1. One-Sentence Summary
   2. Quick Overview
   3. Why This Evaluation Cannot Be Completed
   4. Safety Considerations
   5. Conclusion and Next Steps
   6. Disclaimer

---

## 藥師評估報告

BROLUCIZUMAB: Evaluation Incomplete — Critical Data Gaps Identified

One-Sentence Summary

BROLUCIZUMAB (DrugBank ID: DB14864) is a candidate flagged for drug repurposing analysis, but the current Evidence Pack contains insufficient data to support a complete evaluation. No TxGNN-predicted indications were returned, and critical drug-level data — including original indication, mechanism of action, and safety warnings — are all unavailable. A formal repurposing evaluation cannot be completed at this stage.

---

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	None returned by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 (prediction only — no predictions generated)
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

---

Why This Evaluation Cannot Be Completed

The Evidence Pack for BROLUCIZUMAB has three structural failures that block the evaluation pipeline:

1. No TxGNN predictions generated. The predicted_indications array is empty. This is the core output of the repurposing pipeline — without it, there is no candidate indication to evaluate, no evidence to assess, and no mechanistic hypothesis to test. The TxGNN run for DB14864 must be investigated and re-executed.

2. No original indication recorded. The original_indications field is empty, making it impossible to establish the baseline clinical profile or reason about therapeutic class proximity to any new indication.

3. Mechanism of action unavailable. MOA data (Data Gap DG002, severity: High) has not been retrieved. Without knowing how the drug works, mechanistic plausibility for any repurposing candidate cannot be assessed.

---

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Data Gap DG001 (severity: Blocking): TFDA package insert warnings and contraindications have not been parsed. This gap blocks the safety screening step (S1 initial safety assessment) entirely.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete. No repurposing candidates have been generated by TxGNN, and two blocking data gaps (DG001, DG002) prevent both mechanistic analysis and safety screening. Proceeding without these inputs would produce a report with no evaluable content.

To proceed, the following is needed:

1. Re-run TxGNN prediction for DB14864 — Investigate why predicted_indications is empty. Check whether BROLUCIZUMAB is present in the knowledge graph and whether the prediction job completed successfully. Regenerate predictions.
2. Retrieve original indications — Query DrugBank or TFDA records to populate original_indications.
3. Retrieve MOA data (DG002) — Query the DrugBank API for BROLUCIZUMAB's mechanism of action.
4. Parse package insert for safety data (DG001) — Download the TFDA package insert PDF and extract warnings and contraindications to unblock safety screening.
5. Resubmit Evidence Pack — Once the above four items are resolved, regenerate the Evidence Pack (v5) and rerun this evaluation.

   Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---